Study links age, insurance, but not race, to chemo rates

August 10, 2012
Study links age, insurance, but not race, to chemo rates
For women with breast cancer, disease characteristics correlate significantly with chemotherapy receipt, with no indication of racial barriers to treatment, according to a study published online Aug. 6 in the Journal of Clinical Oncology.

(HealthDay) -- For women with breast cancer, disease characteristics correlate significantly with chemotherapy receipt, with no indication of racial barriers to treatment, according to a study published online Aug. 6 in the Journal of Clinical Oncology.

To examine disparities in receipt of adjuvant chemotherapy, Jennifer J. Griggs, M.D., M.P.H., from the University of Michigan in Ann Arbor, and colleagues recruited women diagnosed with and identified through the Detroit, Michigan, or Los Angeles County Surveillance, Epidemiology, and End Results registry to complete a survey.

The researchers found that, for the 1,403 women included in the analytic sample, disease characteristics correlated significantly with receipt of chemotherapy in multivariable models. Low-acculturated Hispanics and high-acculturated Hispanics were more likely to receive chemotherapy than non-Hispanic whites (odds ratio [OR], 2.00 and 1.43, respectively). Black women were less likely than non-Hispanic whites to receive chemotherapy, but the difference was not significant (OR, 0.83; 95 percent confidence interval, 0.64 to 1.08). Even in women younger than 50 years of age, increasing age correlated with lower rates of chemotherapy receipt, as did Medicaid insurance.

"In conclusion, it seems that race and ethnicity need not pose barriers to receipt of ," the authors write. "Such a finding is encouraging as we continue to address racial and in the receipt of quality cancer care. Nonetheless, differences and disparities do exist in receipt of chemotherapy according to age, insurance, and employment status."

Explore further: Gene expression profile testing increasing in breast cancer

More information: Abstract
Full Text (subscription or payment may be required)
Editorial

Related Stories

Gene expression profile testing increasing in breast cancer

May 18, 2012
(HealthDay) -- From 2006 to 2008, the use of gene expression profile (GEP) testing increased, correlating with a decrease in the percentage of women with hormone receptor (HR)-positive breast cancer receiving adjuvant chemotherapy, ...

Even with insurance, racial disparities in breast cancer treatment persist

July 27, 2012
More White women are diagnosed with breast cancer than Black women, yet Black women with breast cancer have a higher mortality rate. One potential explanation for this disparity is delayed treatment, perhaps due to differences ...

Recommended for you

Shooting the achilles heel of nervous system cancers

July 20, 2017
Virtually all cancer treatments used today also damage normal cells, causing the toxic side effects associated with cancer treatment. A cooperative research team led by researchers at Dartmouth's Norris Cotton Cancer Center ...

Molecular changes with age in normal breast tissue are linked to cancer-related changes

July 20, 2017
Several known factors are associated with a higher risk of breast cancer including increasing age, being overweight after menopause, alcohol intake, and family history. However, the underlying biologic mechanisms through ...

Immune-cell numbers predict response to combination immunotherapy in melanoma

July 20, 2017
Whether a melanoma patient will better respond to a single immunotherapy drug or two in combination depends on the abundance of certain white blood cells within their tumors, according to a new study conducted by UC San Francisco ...

Discovery could lead to better results for patients undergoing radiation

July 19, 2017
More than half of cancer patients undergo radiotherapy, in which high doses of radiation are aimed at diseased tissue to kill cancer cells. But due to a phenomenon known as radiation-induced bystander effect (RIBE), in which ...

Definitive genomic study reveals alterations driving most medulloblastoma brain tumors

July 19, 2017
The most comprehensive analysis yet of medulloblastoma has identified genomic changes responsible for more than 75 percent of the brain tumors, including two new suspected cancer genes that were found exclusively in the least ...

Novel CRISPR-Cas9 screening enables discovery of new targets to aid cancer immunotherapy

July 19, 2017
A novel screening method developed by a team at Dana-Farber/Boston Children's Cancer and Blood Disorders Center—using CRISPR-Cas9 genome editing technology to test the function of thousands of tumor genes in mice—has ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.